Navigation Links
Palomar Successful in U.S. Patent Office Re-Examination of Second Hair Removal Patent
Date:8/18/2009

ready been licensed to ten competitors and is also the subject of a patent infringement lawsuit against Tria Beauty, Inc.

Chief Executive Officer Joseph P. Caruso commented, "We are again very pleased with this result from the U.S. Patent Office. This patent family is strong as is evidenced by the number of our current licensees; as well as the fact that companies are now coming to us for licenses prior to entering the hair removal market."

Mr. Caruso continued, "As I have said in the past, Palomar exclusively licensed the '844 and '568 patents from Massachusetts General Hospital in 1995. Palomar was the first company to receive FDA clearance and bring a high powered light-based hair removal system to market. Palomar was later the first company to receive FDA clearance for permanent hair reduction and the first company to receive over the counter clearance from the FDA for a hair removal device. After establishing light-based hair removal as a viable treatment option, many competitors began to use our technology. Several properly took licenses while others opted not to at their own risk. Unauthorized taking of technology is what the patent system is designed to prevent. We intend to continue our aggressive patent enforcement strategy both to protect our own investment in research and market development as well as the investment of our competitor licensees."

Patricia Davis, Palomar's General Counsel and a registered patent attorney, commented, "Again we are pleased but not surprised by the U.S. Patent Office's position which supports our belief in the strength of both the '568 patent and the patent family as a whole. If Palomar prevails at trial, Candela and Syneron may be ordered to pay significant amounts in damages for past sales and ordered to stop selling infringing products. Palomar also alleges that Candela's and Syneron's activities constitute willful infringement. If Palomar prevails on such c
'/>"/>

SOURCE Palomar Medical Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Palomar Medical Reports Financial Results for Second Quarter 2009
2. Palomar Medical Technologies To Host Second Quarter 2009 Financial Results Conference Call and Webcast on July 30, 2009
3. Palomar Successful in U.S. Patent Office Re-Examination of Hair Removal Patent
4. Palomar Receives FDA Over-The-Counter Clearance for a Home Use Wrinkle Removal Laser Device
5. Palomar Wins Two European Hair Removal Patent Opposition Hearings
6. Palomar Pomerado Health System Achieves National Recognition for Nursing Excellence by the American Nurses Credentialing Center
7. Palomar Medical to Market Quantels SINON Tattoo Removal Laser in the United States and Canada
8. 23andMe and Palomar Pomerado Health Partner to Give PPH Members Access to Their Genetic Information
9. Palomar Medical Technologies to Host First Quarter 2009 Financial Results Conference Call and Webcast on April 30, 2009
10. Palomar Medical to Debut New Devices and a More Powerful Platform at the American Academy of Dermatology Annual Meeting
11. Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... Hospital Pediatrician-in-Chief Jon McCullers, MD, was recently invited ... of Nature Reviews Microbiology , one of ... a world-renowned infectious disease specialist, and chair of ... Tennessee Health Science Center, analyzed the epidemiology and ... 1968 pandemics, as well as more recent 2009 ...
(Date:4/17/2014)... MAYWOOD, Il. (April 17, 2014) Doctors who ... disease called lymphangioleiomyomatosis (LAM) can face an agonizing ... progression of the disease and help relieve shortness ... lung transplants, and sirolimus can cause potentially fatal ... said pulmonologist Dr. Daniel Dilling, medical director of ...
(Date:4/17/2014)... 2014-- Colic affects about one in five infants in ... visits during the first several months after birth. Research ... showing promise; however, the April 1, 2014 issue of ... reported on a study, "Probiotics and Infant Colic," concluding ... for infant colic did not reduce crying ...
(Date:4/17/2014)... 17, 2014 EcoHealth Alliance, a nonprofit organization that ... a comprehensive review today examining the current state of ... review calls for improved global surveillance strategies to combat ... outbreak of Ebola in West Africa that has claimed ... Guinea and Liberia. According to the World Health ...
(Date:4/17/2014)... led by Cesar A. Arias, M.D., Ph.D., at The ... has identified a new superbug that caused a bloodstream ... the April 17 issue of The New England ... part of a class of highly-resistant bacteria known as ... a major cause of hospital and community-associated infections. The ...
Breaking Medicine News(10 mins):Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:New MRSA superbug emerges in Brazil 2
... Retardation -, PHILADELPHIA, Oct. 9 When ... ring before birth, they may,disrupt normal development and ... Children,s Hospital of Philadelphia will be investigating,one such ... Ring Chromosome,20 Foundation., Ring chromosome 20 syndrome, ...
... 9 House Republican Whip Roy,Blunt (Mo.) issued ... Clyburn (D-S.C.) yesterday suggested on CNN that Democrats ... the president,s veto of the,SCHIP bill:, "Yesterday, ... be,hard-pressed to override the president,s veto of a ...
... Quebec City, October 9, 2007People who experience chronic job ... of suffering from a second one, reports a research ... October 10 issue of the Journal of the American ... clearly demonstrate the risks associated with job strain for ...
... Oct. 9 Recent studies by Best,Practices, LLC ... 34 R&D,FTE,s per Quality FTE in Pharmaceutical companies. ... employees to effectively use a,Risk-Based Approach. Does your ... structure for Quality Assurance in R&D? What tools,are ...
... WASHINGTON, Oct. 9 The following was released,today by ... EDT, MR. TENPAS: Good morning. I am ... and Natural Resources Division here at the,Department of ... EPA,s,assistant administrator for Enforcement and Compliance Assurance., ...
... to boost abstinence, study finds , , TUESDAY, Oct. 9 ... seizures could be added to the short list of ... new study suggests. , The drug topiramate proved measurably ... from heavy drinking, the study authors said. , "Not ...
Cached Medicine News:Health News:Grant Supports Study of Abnormal Ring-Shaped Chromosomes 2Health News:Chronic job strain doubles the risk of a second heart attack 2Health News:Best Practice Database: Complimentary Excerpt of Pharma Quality Assurance Toolkit Available from Best Practices, LLC 2Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 2Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 3Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 4Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 5Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 6Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 7Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 8Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 9Health News:Epilepsy Drug Holds Promise as Treatment for Alcoholism 2Health News:Epilepsy Drug Holds Promise as Treatment for Alcoholism 3
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... , Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ... the fourth quarter of 2013 on Monday, February 3, 2014. ... after the close of trading. (Logo: ... to discuss the operating highlights and financial results for the ...
(Date:1/14/2014)... 2014 Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company ... Progressive Home Medical Equipment, Inc. ("Progressive") of Clarion, ... the acquisition were not disclosed. Progressive is ... wide range of sleep, mobility, and respiratory products to customers ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... EAST SETAUKET, N.Y., Aug. 12 Lixte,Biotechnology Holdings, ... had filed a patent application for the use ... brain tumors as potential treatments for,neurodegenerative diseases including ... Kovach, President and CEO of Lixte, said, "Lixte ...
... DIEGO, Aug. 12 MabVax Therapeutics, Inc., ... focused,on the development and commercialization of novel ... the completion of two separate,licensing agreements with ... Cancer Research (SKI)., (Logo: http://www.newscom.com/cgi-bin/prnh/20080812/LATU515LOGO ...
Cached Medicine Technology:Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases 2MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research 2
Stab incision blades color coded for simple and accurate identification...
Smooth, round edges allow for safe manipulation within the eye. 1.1mm wide gradually tapers to .50 mm wide. 45, 1.1mm wide, gradually tapers to .50mm wide....
... has two perforations which enable ... various single or bilateral configurations ... drape has two perforations which ... to various single or bilateral ...
30, 6.0mm from end...
Medicine Products: